CIRCOR (CIR) Appoints Bruce Lisman to Board

CIRCOR International, Inc. (NYSE: CIR) today announced that Bruce Lisman will be appointed to its Board of Directors promptly following the 2020 Annual Meeting of Stockholders. With this appointment, the Board will expand to nine directors, eight of whom are independent. GAMCO Asset Management Inc. (“GAMCO”) has withdrawn its director nominations and plans to vote all of its shares in favor of each of the CIRCOR Board’s nominees at the Company’s upcoming Annual Meeting. Mr. Lisman had been one of GAMCO’s nominees.

“We are pleased to welcome Bruce to the Board,” said David Dietz, Chairman of CIRCOR. “We look forward to working with Bruce and benefitting from his experience and perspective as we work to create value for our shareholders.”

About Bruce M. Lisman

Bruce M. Lisman is a director of four companies; two private and two public. Since 2004, he has served on the Board of the National Life Group, a mutual life insurance company; since 2013 he has served on the Board of PC Construction, an engineering and construction company. In addition, he has served since 2015 on the Board of Myers Industries, Inc., a material handling and distribution company; and, Associated Capital Group, Inc., a financial services company. At those boards, he has served in leadership positions that include Chairman of the Board, Compensation and Governance Committees. Before his retirement Mr. Lisman was the Chairman of JP Morgan Global Equities from 2008 to 2009. Before that he was Co-Head of the Global Equities Division at Bear Stearns, with revenues of $2.2 billion from 1987 to 2008.

He previously served on the boards of Merchants Bancshares and The Pep Boys – Manny, Moe & Jack and on the boards of The Hewitt School, Pace University, Shelburne Museum, and the Vermont Symphony Orchestra. Mr. Lisman is a graduate of the University of Vermont and also served as the Chairman of the university’s board.

You May Also Be Interested In

• VICI Properties closes $1.75B senior unsecured notes offering
• Trinity Biotech secures $7M from Perceptive, regains Nasdaq compliance
• Faeth Therapeutics names two SVPs ahead of clinical milestones